CA2995096A1 - Therapeutic compositions including mitochondrial cell-penetrating peptides, glutathione analog peptides, and fusions thereof, and uses of the compositions to treat and prevent mitochondrial diseases and conditions - Google Patents
Therapeutic compositions including mitochondrial cell-penetrating peptides, glutathione analog peptides, and fusions thereof, and uses of the compositions to treat and prevent mitochondrial diseases and conditions Download PDFInfo
- Publication number
- CA2995096A1 CA2995096A1 CA2995096A CA2995096A CA2995096A1 CA 2995096 A1 CA2995096 A1 CA 2995096A1 CA 2995096 A CA2995096 A CA 2995096A CA 2995096 A CA2995096 A CA 2995096A CA 2995096 A1 CA2995096 A1 CA 2995096A1
- Authority
- CA
- Canada
- Prior art keywords
- deficiency
- syndrome
- mitochondrial
- levels
- myopathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Disclosed herein are methods and compositions related to the treatment and/or amelioration of diseases and conditions comprising administration of mitochondrial antioxidative penetrating peptides (MAPPs), or pharmaceutically acceptable salts thereof. In particular, the present technology relates to administering an effective amount of a MAPP to a subject in need thereof to prevent or treat a disease or medical condition, reduce risk factors associated with a disease or medical condition, and/or reducing the severity of a medical disease or condition.
Description
THERAPEUTIC COMPOSITIONS INCLUDING
MITOCHONDRIAL CELL-PENETRATING PEPTIDES, GLUTATHIONE ANALOG PEPTIDES, AND FUSIONS
THEREOF, AND USES OF THE COMPOSITIONS TO
MITOCHONDRIAL CELL-PENETRATING PEPTIDES, GLUTATHIONE ANALOG PEPTIDES, AND FUSIONS
THEREOF, AND USES OF THE COMPOSITIONS TO
Claims (20)
1. A method for treating or preventing a mitochondrial disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a mitochondrial antioxidative penetrating peptide (MAPP) or a pharmaceutically acceptable salt thereof, in combination with one or more additional therapeutic agents selected from the group consisting of: vitamins, cofactors, antibiotics, hormones, antineoplastic agents, steroids, immunomodulators, dermatologic drugs, antithrombotic, antianemic, and cardiovascular agents.
2. The method of claim 1, wherein the mitochondrial disease or disorder is selected from the group consisting of Alexander disease, Alpers Syndrome, Alpha-ketoglutarate dehydrogenase (AKDGH) deficiency, ALS-FTD, Sideroblastic anemia with spinocerebellar ataxia, Pyridoxine-refractory sideroblastic anemia, GRACILE Syndrome, Björnstad Syndrome, Leigh Syndrome, mitochondrial complex III deficiency nuclear type 1 (MC3DN1), combined oxidative phosphorylation deficiency 18 (COXPD18), Thiamine-responsive megaloblastic anemia syndrome (TRMA), Pearson Syndrome, HAM Syndrome, Ataxia, Cataract, and Diabetes Syndrome, MELAS/MERRF
Overlap Syndrome, combined oxidative phosphorylation deficiency-14 (COXPD1 4), Infantile cerebellar-retinal degeneration (ICRD), Charlevoix-Saguenay spastic ataxia, Primary coenzyme Q10 deficiency-1 (COQ10D1), ataxia oculomotor apraxia type 1 (AOA1), Autosomal recessive spinocerebellar ataxia-9/ coenzyme Q10 deficiency-4 (COQ10D4), Ataxia, Pyramidal Syndrome, and Cytochrome Oxidase Deficiency, Friedreich's ataxia, Infantile onset spinocerebellar ataxia (IOSCA)/ Mitochondrial DNA
Depletion Syndrome-7, Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL), Autosomal recessive spastic ataxia-3 (SPAX3), MIRAS, SANDO, mitochondrial spinocerebellar ataxia and epilepsy (MSCAE), spastic ataxia with optic atrophy (SPAX4), progressive external ophthalmoplegia with mitochondrial DNA deletions autosomal dominant type 5 (PEOA5), mitochondrial complex III deficiency nuclear type 2 (MC3DN2), episodic encephalopathy due to thiamine pyrophosphokinase deficiency/Thiamine Metabolism Dysfunction Syndrome-5 (THMD5), Spinocerebellar ataxia-28 (SCA28), autosomal dominant cerebellar ataxia, deafness, and narcolepsy (ADCA-DN), Dominant Optic Atrophy (DOA), cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss (CAPOS) Syndrome, spinocerebellar ataxia 7 (SCA7), Barth Syndrome, Biotinidase deficiency, gyrate atrophy, Syndromic Dominant Optic Atrophy and Deafness (Syndromic DOAD), Dominant Optic Atrophy plus (D0Ap1us), Leber's hereditary optic neuropathy (LHON), Wolfram Syndrome-1 (WFS1), Wolfram Syndrome-2 (WFS2), Age-related macular degeneration (ARMD), Brunner Syndrome, Left ventricular noncompaction-1 (LVNC1), histiocytoid cardiomyopathy, Familial Myalgia Syndrome, Parkinsonism, Fatal infantile cardioencephalomyopathy due to cytochrome c oxidase (COX) deficiency-1 (CEMCOX1), Sengers Syndrome, Cardiofaciocutaneous Syndrome-1 (CFC1), Mitochondrial trifunctional protein (MTP) deficiency, infantile encephalocardiomyopathy with cytochrome c oxidase deficiency, cardiomyopathy + encephalomyopathy, mitochondrial phosphate carrier deficiency, infantile cardioencephalomyopathy due to cytochrome c oxidase (COX) deficiency (CEMCOX2), .beta.-Hydroxyisobutyryl CoA Deacylase (HIBCH) deficiency, ECHS1) deficiency, Maternal Inheritance Leigh Syndrome (MILS), dilated cardiomyopathy with ataxia (DCMA), Mitochondrial DNA Depletion Syndrome-12 (MTDPS12), cardiomyopathy due to mitochondrial tRNA deficiencies, mitochondrial complex V (ATP
synthase) deficiency nuclear type 1 (MC5DN1), combined oxidative phosphorylation deficiency-8 (COXPD8), progessive leukoencephalopathy with ovarian failure (LKENP), combined oxidative phosphorylation deficiency-10 (COXPD10), combined oxidative phosphorylation deficiency-16 (COXPD16), combined oxidative phosphorylation deficiency-17 (COXPD17), combined oxidative phosphorylation deficiency-5 (COXPD5), combined oxidative phosphorylation deficiency-9 (COXPD9), carnitine acetyltransferase (CRAT) deficiency, carnitine palmitoyltransferase I (CPT I) deficiency, myopathic carnitine deficiency, primary systemic carnitine deficiency (CDSP), carnitine palmitoyltransferase II (CPT II) deficiency, carnitine-acylcarnitine translocase deficiency (CACTD), cartilage-hair hypoplasia, cerebrotendinous xanthomatosis (CTX), congenital adrenal hyperplasia (CAH), megaconial type congenital muscular dystrophy, cerebral creatine deficiency syndrome-3 (CCDS3), maternal nonsyndromic deafness, maternal nonsyndromic deafness, autosomal dominant deafness-64 (DFNA64), Mohr-Tranebjaerg Syndrome, Jensen Syndrome, MEGDEL, reticular dysgenesis, primary coenzyme Q10 deficiency-6 (COQ10D6), CAGSSS, diabetes, Dimethylglycine dehydrogenase deficiency (DMGDHD), Multiple Mitochondrial Dysfunctions Syndrome-1 (MMDS1), Multiple Mitochondrial Dysfunctions Syndrome-2 (MMDS2), Multiple Mitochondrial Dysfunctions Syndrome-3 (MMDS3), childhood leukoencephalopathy associated with mitochondrial Complex II deficiency, encephalopathies associated with mitochondrial Complex I deficiency, encephalopathies associated with mitochondrial Complex III deficiency, encephalopathies associated with mitochondrial Complex IV deficiency, encephalopathies associated with mitochondrial Complex V deficiency, hyperammonemia due to carbonic anhydrase VA deficiency (CA5AD), early infantile epileptic encephalopathy-3 (EIEE3), 2,4-Dienoyl-CoA reductase deficiency (DECRD), infection-induced acute encephalopathy-3 (IIAE3), ethylmalonic encephalopathy (EE), hypomyelinating leukodystrophy (HLD4), exocrine pancreatic insufficiency, dyserythropoietic anemia and calvarial hyperostosis, Glutaric aciduria type 1 (GA-1), glycine encephalopathy (GCE), hepatic failure, 2-hydroxyglutarie aciduria, 3-hydroxyacyl-CoA dehydrogenase deficiency, familial hyperinsulinemic hypoglycemia (FHH), hypercalcemia infantile, hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) Syndrome, Immunodeficiency with hyper-IgM type 5 (HIGM5), Inclusion Body Myositis (IBM), polymyositis with mitochondrial pathology, IM-Mito, granulomatous myopathies with anti-mitochondrial antibodies, necrotizing myopathy with pipestem capillaries, myopathy with deficient chondroitin sulfate C in skeletal muscle connective tissue, benign acute childhood myositis, idiopathic orbital myositis, masticator myopathy, hemophagocytic lymphohistiocytosis, infection-associated myositis, Facioscapulohumeral dystrophy (FSH), familial idiopathic inflammatory myopathy, Schmidt Syndrome (Diabetes mellitus, Addison disease, Myxedema), TNF receptor-associated Periodic Syndrome (TRAPS), focal myositis, autoimmune fasciitis, Spanish toxic oil-associated fasciitis, Eosinophilic fasciitis, Macrophagic myofasciitis, Graft-vs-host disease fasciitis, Eosinophilia-myalgia Syndrome, perimyositis, isovaleric acidemia (IVA), Kearnes-Sayre Syndrome (KSS), 2-oxoadipic aciduria, 2-aminoadipic aciduria, Limb-girdle Muscular Dystrophy Syndromes, leukodystrophy, Maple syrup urine disease (MSUD), 3-Methylcrotonyl-CoA carboxylase (MCC), Methylmalonic aciduria (MMA), Miller Syndrome, Mitochondrial DNA Depletion Syndrome-2 (MTDPS2), spinal muscular atrophy syndrome, rigid spine syndrome, severe myopathy with motor regression, Mitochondrial DNA Depletion Syndrome-3, MELAS
Syndrome, camptocormia, MNGIE, MNGIM Syndrome, Menkes Disease, Occipital Horn Syndrome, X-linked distal spinal muscular atrophy-3 (SMAX3), methemoglobinemia, MERRF, progressive external ophthalmoplegia with myoclonus, deafness and diabetes (DD), multiple symmetric lipomatosis, Myopathy with Episodic high Creatine Kinase (MIMECK), Epilepsia Partialis Continua, malignant hyperthermia syndromes, glycogen metabolic disorders, fatty acid oxidation and lipid metabolism disorders, medication-, drug- or toxin-induced myoglobinuria, mitochondrial disorder-associated myoglobinuria, hypokalemic myopathy and rhabdomyolysis, muscle trauma-associated myoglobinuria, ischemia-induced myoglobinuria, infection-induced myoglobinuria, immune myopathies associated with myoglobinuria, Myopathy, lactic acidosis, and sideroblastic anemia (MLASA), infantile mitochondrial myopathy due to reversible COX
deficiency (MMIT), Myopathy, Exercise intolerance, Encephalopathy and Lactic acidemia Syndrome, myoglobinuria and exercise intolerance syndrome, exercise intolerance, proximal weakness myoglobinuria syndrome, encephalopathy and seizures syndrome, septo-optic dysplasia, exercise intolerance mild weakness, myopathy exercise intolerance, growth or CNS
disorder, maternally-inherited mitochondrial myopathies, myopathy with lactic acidosis, myopathy with rhabdomyolysis, Myopathy with cataract and combined respiratory chain deficiency, myopathy with abnormal mitochondrial translation, Fatigue Syndrome, myopathy with extrapyramidal movement disorders (MPXPS), glutaric aciduria II (MADD), primary CoQ10 deficiency-1 (COQ10D1), primary CoQ10 deficiency-2 (COQ10D2), primary CoQ10 deficiency-3 (COQ10D3), primary CoQ10 deficiency-5 (COQ10D5), secondary CoQ10 deficiency, autosomal dominant mitochondrial myopathy, myopathy with focal depletion of mitochondria, mitochondrial DNA breakage syndrome (PEO + Myopathy), lipid type mitochondrial myopathy, multiple symmetric lipomatosis (MSL), N-acetylglutamate synthase (NAGS) deficiency, Nephronophthisis (NPHP), ornithine transcarbamylase (OTC) deficiency, neoplasms, NARP Syndrome, paroxysmal nonkinesigenic dyskinesia (PNKD), sporadic PEO, maternally-inherited PEO, autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA
deletions-3 (PEOA3), autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions-2 (PEOA2), autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA
deletions-1 (PEOA1), PEO+ demyelinating neuropathy, PEO +
hypogonadism, autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions-4 (PEOA4), distal myopathy, cachexia &
PEO, autosomal dominant progressive external ophthalmoplegia-6 (PEOA6), PEO + Myopathy and Parkinsonism, autosomal recessive progressive external ophthalmoplegia (PEOB), Mitochondrial DNA Depletion Syndrome-11 (MTDPS11), PEO with cardiomyopathy, PEPCK deficiency, Perrault Syndromes (PRLTS), propionic acidemia (PA), pyruvate carboxylase deficiency, pyruvate dehydrogenase E1-alpha deficiency (PDHAD), pyruvate dehydrogenase E1-beta deficiency (PDHBD), dihydrolipoamide dehydrogenase (DLD) deficiency, pyruvate dehydrogenase phosphatase deficiency, pyruvate dehydrogenase E3-binding protein deficiency (PDHXD), mitochondrial pyruvate carrier deficiency (MPYCD), Schwartz-Jampel Syndrome type 1 (SJS1), selenium deficiency, short-chain acyl-CoA
dehydrogenase (SCAD) deficiency, succinyl CoA:3-oxacid CoA transferase (SCOT) deficiency, Stuve-Wiedemann Syndrome (STWS), thrombocytopenia (THC), Very long-chain acyl-CoA dehydrogenase deficiency (VLCADD), Vitamin D-dependent rickets type 1A (VDDR1A), Wilson's disease, Zellweger Syndrome (PBD3A), arsenic trioxide myopathy, myopathy and neuropathy resulting from nucleoside analogs, germanium myopathy, Parkinsonism and mitochondrial Complex I neurotoxicity due to trichloroethylene, valproate-induced hepatic failure, neurodegeneration with brain iron accumulation-4 (NBIA4), Complex I deficiency, Complex II
deficiency, Complex III deficiency, Complex IV deficiency, Complex V
deficiency, Cytochrome c oxidase (COX) deficiency, combined complex I, II, IV, V deficiency, combined complex I, II, and III deficiency, combined oxidative phosphorylation deficiency-1 (COXPD1), combined oxidative phosphorylation deficiency-2 (COXPD2), combined oxidative phosphorylation deficiency-3 (COXPD3), combined oxidative phosphorylation deficiency-4 (COXPD4), combined oxidative phosphorylation deficiency-6 (COXPD6), combined oxidative phosphorylation deficiency-7 (COXPD7), combined oxidative phosphorylation deficiency-9 (COXPD9), combined oxidative phosphorylation deficiency-11 (COXPD11), combined oxidative phosphorylation deficiency-12 (COXPD12), combined oxidative phosphorylation deficiency-13 (COXPD13), combined oxidative phosphorylation deficiency-15 (COXPD15), combined oxidative phosphorylation deficiency-16 (COXPD16), combined oxidative phosphorylation deficiency-19 (COXPD19), combined oxidative phosphorylation deficiency-20 (COXPD20), combined oxidative phosphorylation deficiency-21 (COXPD21), fumarase deficiency, HMG-CoA
synthase-2 deficiency, hyperuricemia, pulmonary hypertension, renal failure, and alkalosis (HUPRA) Syndrome, syndromic microphthalmia-7, pontocerebellar hypoplasia type 6 (PCH6), Mitochondrial DNA Depletion Syndrome-9 (MTDPS9P), and Sudden infant death Syndrome (SIDS).
Overlap Syndrome, combined oxidative phosphorylation deficiency-14 (COXPD1 4), Infantile cerebellar-retinal degeneration (ICRD), Charlevoix-Saguenay spastic ataxia, Primary coenzyme Q10 deficiency-1 (COQ10D1), ataxia oculomotor apraxia type 1 (AOA1), Autosomal recessive spinocerebellar ataxia-9/ coenzyme Q10 deficiency-4 (COQ10D4), Ataxia, Pyramidal Syndrome, and Cytochrome Oxidase Deficiency, Friedreich's ataxia, Infantile onset spinocerebellar ataxia (IOSCA)/ Mitochondrial DNA
Depletion Syndrome-7, Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL), Autosomal recessive spastic ataxia-3 (SPAX3), MIRAS, SANDO, mitochondrial spinocerebellar ataxia and epilepsy (MSCAE), spastic ataxia with optic atrophy (SPAX4), progressive external ophthalmoplegia with mitochondrial DNA deletions autosomal dominant type 5 (PEOA5), mitochondrial complex III deficiency nuclear type 2 (MC3DN2), episodic encephalopathy due to thiamine pyrophosphokinase deficiency/Thiamine Metabolism Dysfunction Syndrome-5 (THMD5), Spinocerebellar ataxia-28 (SCA28), autosomal dominant cerebellar ataxia, deafness, and narcolepsy (ADCA-DN), Dominant Optic Atrophy (DOA), cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss (CAPOS) Syndrome, spinocerebellar ataxia 7 (SCA7), Barth Syndrome, Biotinidase deficiency, gyrate atrophy, Syndromic Dominant Optic Atrophy and Deafness (Syndromic DOAD), Dominant Optic Atrophy plus (D0Ap1us), Leber's hereditary optic neuropathy (LHON), Wolfram Syndrome-1 (WFS1), Wolfram Syndrome-2 (WFS2), Age-related macular degeneration (ARMD), Brunner Syndrome, Left ventricular noncompaction-1 (LVNC1), histiocytoid cardiomyopathy, Familial Myalgia Syndrome, Parkinsonism, Fatal infantile cardioencephalomyopathy due to cytochrome c oxidase (COX) deficiency-1 (CEMCOX1), Sengers Syndrome, Cardiofaciocutaneous Syndrome-1 (CFC1), Mitochondrial trifunctional protein (MTP) deficiency, infantile encephalocardiomyopathy with cytochrome c oxidase deficiency, cardiomyopathy + encephalomyopathy, mitochondrial phosphate carrier deficiency, infantile cardioencephalomyopathy due to cytochrome c oxidase (COX) deficiency (CEMCOX2), .beta.-Hydroxyisobutyryl CoA Deacylase (HIBCH) deficiency, ECHS1) deficiency, Maternal Inheritance Leigh Syndrome (MILS), dilated cardiomyopathy with ataxia (DCMA), Mitochondrial DNA Depletion Syndrome-12 (MTDPS12), cardiomyopathy due to mitochondrial tRNA deficiencies, mitochondrial complex V (ATP
synthase) deficiency nuclear type 1 (MC5DN1), combined oxidative phosphorylation deficiency-8 (COXPD8), progessive leukoencephalopathy with ovarian failure (LKENP), combined oxidative phosphorylation deficiency-10 (COXPD10), combined oxidative phosphorylation deficiency-16 (COXPD16), combined oxidative phosphorylation deficiency-17 (COXPD17), combined oxidative phosphorylation deficiency-5 (COXPD5), combined oxidative phosphorylation deficiency-9 (COXPD9), carnitine acetyltransferase (CRAT) deficiency, carnitine palmitoyltransferase I (CPT I) deficiency, myopathic carnitine deficiency, primary systemic carnitine deficiency (CDSP), carnitine palmitoyltransferase II (CPT II) deficiency, carnitine-acylcarnitine translocase deficiency (CACTD), cartilage-hair hypoplasia, cerebrotendinous xanthomatosis (CTX), congenital adrenal hyperplasia (CAH), megaconial type congenital muscular dystrophy, cerebral creatine deficiency syndrome-3 (CCDS3), maternal nonsyndromic deafness, maternal nonsyndromic deafness, autosomal dominant deafness-64 (DFNA64), Mohr-Tranebjaerg Syndrome, Jensen Syndrome, MEGDEL, reticular dysgenesis, primary coenzyme Q10 deficiency-6 (COQ10D6), CAGSSS, diabetes, Dimethylglycine dehydrogenase deficiency (DMGDHD), Multiple Mitochondrial Dysfunctions Syndrome-1 (MMDS1), Multiple Mitochondrial Dysfunctions Syndrome-2 (MMDS2), Multiple Mitochondrial Dysfunctions Syndrome-3 (MMDS3), childhood leukoencephalopathy associated with mitochondrial Complex II deficiency, encephalopathies associated with mitochondrial Complex I deficiency, encephalopathies associated with mitochondrial Complex III deficiency, encephalopathies associated with mitochondrial Complex IV deficiency, encephalopathies associated with mitochondrial Complex V deficiency, hyperammonemia due to carbonic anhydrase VA deficiency (CA5AD), early infantile epileptic encephalopathy-3 (EIEE3), 2,4-Dienoyl-CoA reductase deficiency (DECRD), infection-induced acute encephalopathy-3 (IIAE3), ethylmalonic encephalopathy (EE), hypomyelinating leukodystrophy (HLD4), exocrine pancreatic insufficiency, dyserythropoietic anemia and calvarial hyperostosis, Glutaric aciduria type 1 (GA-1), glycine encephalopathy (GCE), hepatic failure, 2-hydroxyglutarie aciduria, 3-hydroxyacyl-CoA dehydrogenase deficiency, familial hyperinsulinemic hypoglycemia (FHH), hypercalcemia infantile, hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) Syndrome, Immunodeficiency with hyper-IgM type 5 (HIGM5), Inclusion Body Myositis (IBM), polymyositis with mitochondrial pathology, IM-Mito, granulomatous myopathies with anti-mitochondrial antibodies, necrotizing myopathy with pipestem capillaries, myopathy with deficient chondroitin sulfate C in skeletal muscle connective tissue, benign acute childhood myositis, idiopathic orbital myositis, masticator myopathy, hemophagocytic lymphohistiocytosis, infection-associated myositis, Facioscapulohumeral dystrophy (FSH), familial idiopathic inflammatory myopathy, Schmidt Syndrome (Diabetes mellitus, Addison disease, Myxedema), TNF receptor-associated Periodic Syndrome (TRAPS), focal myositis, autoimmune fasciitis, Spanish toxic oil-associated fasciitis, Eosinophilic fasciitis, Macrophagic myofasciitis, Graft-vs-host disease fasciitis, Eosinophilia-myalgia Syndrome, perimyositis, isovaleric acidemia (IVA), Kearnes-Sayre Syndrome (KSS), 2-oxoadipic aciduria, 2-aminoadipic aciduria, Limb-girdle Muscular Dystrophy Syndromes, leukodystrophy, Maple syrup urine disease (MSUD), 3-Methylcrotonyl-CoA carboxylase (MCC), Methylmalonic aciduria (MMA), Miller Syndrome, Mitochondrial DNA Depletion Syndrome-2 (MTDPS2), spinal muscular atrophy syndrome, rigid spine syndrome, severe myopathy with motor regression, Mitochondrial DNA Depletion Syndrome-3, MELAS
Syndrome, camptocormia, MNGIE, MNGIM Syndrome, Menkes Disease, Occipital Horn Syndrome, X-linked distal spinal muscular atrophy-3 (SMAX3), methemoglobinemia, MERRF, progressive external ophthalmoplegia with myoclonus, deafness and diabetes (DD), multiple symmetric lipomatosis, Myopathy with Episodic high Creatine Kinase (MIMECK), Epilepsia Partialis Continua, malignant hyperthermia syndromes, glycogen metabolic disorders, fatty acid oxidation and lipid metabolism disorders, medication-, drug- or toxin-induced myoglobinuria, mitochondrial disorder-associated myoglobinuria, hypokalemic myopathy and rhabdomyolysis, muscle trauma-associated myoglobinuria, ischemia-induced myoglobinuria, infection-induced myoglobinuria, immune myopathies associated with myoglobinuria, Myopathy, lactic acidosis, and sideroblastic anemia (MLASA), infantile mitochondrial myopathy due to reversible COX
deficiency (MMIT), Myopathy, Exercise intolerance, Encephalopathy and Lactic acidemia Syndrome, myoglobinuria and exercise intolerance syndrome, exercise intolerance, proximal weakness myoglobinuria syndrome, encephalopathy and seizures syndrome, septo-optic dysplasia, exercise intolerance mild weakness, myopathy exercise intolerance, growth or CNS
disorder, maternally-inherited mitochondrial myopathies, myopathy with lactic acidosis, myopathy with rhabdomyolysis, Myopathy with cataract and combined respiratory chain deficiency, myopathy with abnormal mitochondrial translation, Fatigue Syndrome, myopathy with extrapyramidal movement disorders (MPXPS), glutaric aciduria II (MADD), primary CoQ10 deficiency-1 (COQ10D1), primary CoQ10 deficiency-2 (COQ10D2), primary CoQ10 deficiency-3 (COQ10D3), primary CoQ10 deficiency-5 (COQ10D5), secondary CoQ10 deficiency, autosomal dominant mitochondrial myopathy, myopathy with focal depletion of mitochondria, mitochondrial DNA breakage syndrome (PEO + Myopathy), lipid type mitochondrial myopathy, multiple symmetric lipomatosis (MSL), N-acetylglutamate synthase (NAGS) deficiency, Nephronophthisis (NPHP), ornithine transcarbamylase (OTC) deficiency, neoplasms, NARP Syndrome, paroxysmal nonkinesigenic dyskinesia (PNKD), sporadic PEO, maternally-inherited PEO, autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA
deletions-3 (PEOA3), autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions-2 (PEOA2), autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA
deletions-1 (PEOA1), PEO+ demyelinating neuropathy, PEO +
hypogonadism, autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions-4 (PEOA4), distal myopathy, cachexia &
PEO, autosomal dominant progressive external ophthalmoplegia-6 (PEOA6), PEO + Myopathy and Parkinsonism, autosomal recessive progressive external ophthalmoplegia (PEOB), Mitochondrial DNA Depletion Syndrome-11 (MTDPS11), PEO with cardiomyopathy, PEPCK deficiency, Perrault Syndromes (PRLTS), propionic acidemia (PA), pyruvate carboxylase deficiency, pyruvate dehydrogenase E1-alpha deficiency (PDHAD), pyruvate dehydrogenase E1-beta deficiency (PDHBD), dihydrolipoamide dehydrogenase (DLD) deficiency, pyruvate dehydrogenase phosphatase deficiency, pyruvate dehydrogenase E3-binding protein deficiency (PDHXD), mitochondrial pyruvate carrier deficiency (MPYCD), Schwartz-Jampel Syndrome type 1 (SJS1), selenium deficiency, short-chain acyl-CoA
dehydrogenase (SCAD) deficiency, succinyl CoA:3-oxacid CoA transferase (SCOT) deficiency, Stuve-Wiedemann Syndrome (STWS), thrombocytopenia (THC), Very long-chain acyl-CoA dehydrogenase deficiency (VLCADD), Vitamin D-dependent rickets type 1A (VDDR1A), Wilson's disease, Zellweger Syndrome (PBD3A), arsenic trioxide myopathy, myopathy and neuropathy resulting from nucleoside analogs, germanium myopathy, Parkinsonism and mitochondrial Complex I neurotoxicity due to trichloroethylene, valproate-induced hepatic failure, neurodegeneration with brain iron accumulation-4 (NBIA4), Complex I deficiency, Complex II
deficiency, Complex III deficiency, Complex IV deficiency, Complex V
deficiency, Cytochrome c oxidase (COX) deficiency, combined complex I, II, IV, V deficiency, combined complex I, II, and III deficiency, combined oxidative phosphorylation deficiency-1 (COXPD1), combined oxidative phosphorylation deficiency-2 (COXPD2), combined oxidative phosphorylation deficiency-3 (COXPD3), combined oxidative phosphorylation deficiency-4 (COXPD4), combined oxidative phosphorylation deficiency-6 (COXPD6), combined oxidative phosphorylation deficiency-7 (COXPD7), combined oxidative phosphorylation deficiency-9 (COXPD9), combined oxidative phosphorylation deficiency-11 (COXPD11), combined oxidative phosphorylation deficiency-12 (COXPD12), combined oxidative phosphorylation deficiency-13 (COXPD13), combined oxidative phosphorylation deficiency-15 (COXPD15), combined oxidative phosphorylation deficiency-16 (COXPD16), combined oxidative phosphorylation deficiency-19 (COXPD19), combined oxidative phosphorylation deficiency-20 (COXPD20), combined oxidative phosphorylation deficiency-21 (COXPD21), fumarase deficiency, HMG-CoA
synthase-2 deficiency, hyperuricemia, pulmonary hypertension, renal failure, and alkalosis (HUPRA) Syndrome, syndromic microphthalmia-7, pontocerebellar hypoplasia type 6 (PCH6), Mitochondrial DNA Depletion Syndrome-9 (MTDPS9P), and Sudden infant death Syndrome (SIDS).
3. The method of any one of claims 1-2, wherein the MAPP is administered daily for one, two, three, four or five weeks.
4. The method of any one of claims 1-3, wherein the MAPP is administered daily for 6 weeks or more.
5. The method of claim 1, wherein the subject displays abnormal levels of one or more energy biomarkers compared to a normal control subject.
6. The method of claim 5, wherein the energy biomarker is selected from the group consisting of lactic acid (lactate) levels; pyruvic acid (pyruvate) levels;
lactate/pyruvate ratios; total, reduced or oxidized glutathione levels; total, reduced or oxidized cysteine levels; reduced/oxidized glutathione ratios;
reduced/oxidized cysteine ratios; phosphocreatine levels; NADH
(NADH+H30) or NADPH (NADPH+H30 ) levels; NAD or NADP levels; ATP
levels; reduced coenzyme Q (CoQred) levels; oxidized coenzyme Q (CoQox) levels; total coenzyme Q (CoQtot) levels; oxidized cytochrome C levels;
reduced cytochrome C levels; oxidized cytochrome C/reduced cytochrome C
ratio; acetoacetate levels; beta-hydroxy butyrate levels; acetoacetate/ beta-hydroxy butyrate ratio; 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels; levels of reactive oxygen species; oxygen consumption (VO2), carbon dioxide output (VCO2), and respiratory quotient (VCO2/VO2).
lactate/pyruvate ratios; total, reduced or oxidized glutathione levels; total, reduced or oxidized cysteine levels; reduced/oxidized glutathione ratios;
reduced/oxidized cysteine ratios; phosphocreatine levels; NADH
(NADH+H30) or NADPH (NADPH+H30 ) levels; NAD or NADP levels; ATP
levels; reduced coenzyme Q (CoQred) levels; oxidized coenzyme Q (CoQox) levels; total coenzyme Q (CoQtot) levels; oxidized cytochrome C levels;
reduced cytochrome C levels; oxidized cytochrome C/reduced cytochrome C
ratio; acetoacetate levels; beta-hydroxy butyrate levels; acetoacetate/ beta-hydroxy butyrate ratio; 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels; levels of reactive oxygen species; oxygen consumption (VO2), carbon dioxide output (VCO2), and respiratory quotient (VCO2/VO2).
7. The method of any one of claims 1-6, wherein the subject is human.
8. The method of any one of claims 1-7, wherein the MAPP is administered orally, intranasally, intrathecally, intraocularly, intradermally, transmucosally, iontophoretically, topically, systemically, intravenously, subcutaneously, intraperitoneally, or intramuscularly.
9. The method of claim 1, wherein the symptoms of the mitochondrial disease or disorder comprises one or more of poor growth, loss of muscle coordination, muscle weakness, neurological deficit, seizures, autism, autistic spectrum, autistic-like features, learning disabilities, heart disease, liver disease, kidney disease, gastrointestinal disorders, severe constipation, diabetes, increased risk of infection, thyroid dysfunction, adrenal dysfunction, autonomic dysfunction, confusion, disorientation, memory loss, failure to thrive, poor coordination, sensory (vision, hearing) problems, reduced mental functions, hypotonia, disease of the organ, dementia, respiratory problems, hypoglycemia, apnea, lactic acidosis, seizures, swallowing difficulties, developmental delays, movement disorders (dystonia, muscle spasms, tremors, chorea), stroke, and brain atrophy.
10. The method of any one of claims 1-8, further comprising separately, sequentially or simultaneously administering an additional therapeutic agent to the subject.
11. The method of claim 10, wherein the additional therapeutic agent is selected from the group consisting of: vitamins, cofactors, antibiotics, hormones, antineoplastic agents, steroids, immunomodulators, dermatologic drugs, antithrombotic, antianemic, and cardiovascular agents.
12. A method for modulating the expression of one or more energy biomarkers in a mammalian subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a mitochondrial antioxidative penetrating peptide (MAPP) or a pharmaceutically acceptable salt thereof, in combination with one or more additional therapeutic agents selected from the group consisting of: vitamins, cofactors, antibiotics, hormones, antineoplastic agents, steroids, immunomodulators, dermatologic drugs, antithrombotic, antianemic, and cardiovascular agents.
13. The method of claim 12, wherein the energy biomarker is selected from the group consisting of lactic acid (lactate) levels; pyruvic acid (pyruvate) levels;
lactate/pyruvate ratios; total, reduced or oxidized glutathione levels; total, reduced or oxidized cysteine levels; reduced/oxidized glutathione ratios;
reduced/oxidized cysteine ratios; phosphocreatine levels; NADH
(NADH+H30) or NADPH (NADPH+H30) levels; NAD or NADP levels; ATP
levels; reduced coenzyme Q (CoQred) levels; oxidized coenzyme Q (CoQox) levels; total coenzyme Q (CoQtot) levels; oxidized cytochrome C levels;
reduced cytochrome C levels; oxidized cytochrome C/reduced cytochrome C
ratio; acetoacetate levels; beta-hydroxy butyrate levels; acetoacetate/ beta-hydroxy butyrate ratio; 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels; levels of reactive oxygen species; oxygen consumption (VO2), carbon dioxide output (VCO2), and respiratory quotient (VCO2/VO2).
lactate/pyruvate ratios; total, reduced or oxidized glutathione levels; total, reduced or oxidized cysteine levels; reduced/oxidized glutathione ratios;
reduced/oxidized cysteine ratios; phosphocreatine levels; NADH
(NADH+H30) or NADPH (NADPH+H30) levels; NAD or NADP levels; ATP
levels; reduced coenzyme Q (CoQred) levels; oxidized coenzyme Q (CoQox) levels; total coenzyme Q (CoQtot) levels; oxidized cytochrome C levels;
reduced cytochrome C levels; oxidized cytochrome C/reduced cytochrome C
ratio; acetoacetate levels; beta-hydroxy butyrate levels; acetoacetate/ beta-hydroxy butyrate ratio; 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels; levels of reactive oxygen species; oxygen consumption (VO2), carbon dioxide output (VCO2), and respiratory quotient (VCO2/VO2).
14. The method of any one of claims 12-13, wherein the MAPP is administered daily for one, two, three, four or five weeks.
15. The method of any one of claims 12-14, wherein the MAPP is administered daily for 6 weeks or more.
16. The method of any one of claims 12-15, wherein the subject has been diagnosed has having, is suspected of having, or is at risk of having a mitochondrial disease or disorder.
17. The method of claim 16, wherein symptoms of the mitochondrial disease or disorder comprises one or more of poor growth, loss of muscle coordination, muscle weakness, neurological deficit, seizures, autism, autistic spectrum, autistic-like features, learning disabilities, heart disease, liver disease, kidney disease, gastrointestinal disorders, severe constipation, diabetes, increased risk of infection, thyroid dysfunction, adrenal dysfunction, autonomic dysfunction, confusion, disorientation, memory loss, failure to thrive, poor coordination, sensory (vision, hearing) problems, reduced mental functions, hypotonia, disease of the organ, dementia, respiratory problems, hypoglycemia, apnea, lactic acidosis, seizures, swallowing difficulties, developmental delays, movement disorders (dystonia, muscle spasms, tremors, chorea), stroke, and brain atrophy. .
18. The method of any one of claims 12-17, wherein the subject is human.
19. The method of any one of claims 12-18, wherein the MAPP is administered orally, intranasally, intrathecally, intraocularly, intradermally, transmucosally, iontophoretically, topically, systemically, intravenously, subcutaneously, intraperitoneally, or intramuscularly.
20. The method of any one of claims 1-19, wherein the additional therapeutic agent is administered sequentially or simultaneously to the subject.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2995096A CA2995096A1 (en) | 2018-02-13 | 2018-02-13 | Therapeutic compositions including mitochondrial cell-penetrating peptides, glutathione analog peptides, and fusions thereof, and uses of the compositions to treat and prevent mitochondrial diseases and conditions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2995096A CA2995096A1 (en) | 2018-02-13 | 2018-02-13 | Therapeutic compositions including mitochondrial cell-penetrating peptides, glutathione analog peptides, and fusions thereof, and uses of the compositions to treat and prevent mitochondrial diseases and conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2995096A1 true CA2995096A1 (en) | 2019-08-13 |
Family
ID=67618383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2995096A Abandoned CA2995096A1 (en) | 2018-02-13 | 2018-02-13 | Therapeutic compositions including mitochondrial cell-penetrating peptides, glutathione analog peptides, and fusions thereof, and uses of the compositions to treat and prevent mitochondrial diseases and conditions |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2995096A1 (en) |
-
2018
- 2018-02-13 CA CA2995096A patent/CA2995096A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2884607A1 (en) | Therapeutic compositions including acrylamido compounds or phenyl-substiituted maleimide compounds and uses thereof to treat and prevent mitochondrial diseases and conditions | |
| Hargreaves | Coenzyme Q10 as a therapy for mitochondrial disease | |
| ES2393065T3 (en) | Compositions and procedures for the treatment of mitochondrial diseases | |
| Romano et al. | Cardiomyopathies in propionic aciduria are reversible after liver transplantation | |
| Santa | Treatment options for mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke‐like episodes (MELAS) syndrome | |
| Suomalainen | Therapy for mitochondrial disorders: little proof, high research activity, some promise | |
| JP6313479B2 (en) | Composition of organic selenium compound and method of use thereof | |
| JP2009235101A (en) | Composition and method for treating mitochondrial disease | |
| Almannai et al. | Metabolic seizures | |
| Dolci et al. | Therapeutic induction of energy metabolism reduces neural tissue damage and increases microglia activation in severe spinal cord injury | |
| JP2021120388A (en) | Compositions and Methods for Neuroprotection and Treatment of Neurodegeneration | |
| CA2995096A1 (en) | Therapeutic compositions including mitochondrial cell-penetrating peptides, glutathione analog peptides, and fusions thereof, and uses of the compositions to treat and prevent mitochondrial diseases and conditions | |
| US20210346327A1 (en) | Method for enhancing energy production and metabolism in cells | |
| Latzer et al. | Treatment of neurometabolic epilepsies: overview and recent advances | |
| Novikov et al. | Mitochondrial dysfunctions and antihypoxants | |
| US20080095741A1 (en) | R-(+)-alpha-liponic acid for the prevention of diabetes | |
| Ganesh et al. | Ocular manifestations of inborn errors of metabolism | |
| Pons et al. | Mitochondrial disease | |
| ES2972446T3 (en) | Method to improve white matter integrity in patients with hyperphenylalaninemia and phenylketonuria | |
| Fearon | 12 Nutritional pharmacology in the treatment of neoplastic disease | |
| Orsucci et al. | New therapeutics to modulate mitochondrial energy metabolism in neurodegenerative disorders: the example of mitochondrial disorders | |
| WO2020209059A1 (en) | Pharmaceutical composition for treating hyperammonemia | |
| JP2024519046A (en) | Medical uses of KL1333 | |
| KR20210076040A (en) | TCA circuit intermediates and methods of use thereof | |
| Martinelli | Disorders leading to an impairment of the urea cycle and hyperammonemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20220816 |
|
| FZDE | Discontinued |
Effective date: 20220816 |
|
| FZDE | Discontinued |
Effective date: 20220816 |